US OptionsDetailed Quotes
REGN240802C1070000
- 33.70
- 0.000.00%
15min DelayClose Jul 31 15:59 ET
0.00High0.00Low
33.70Open33.70Pre Close0 Volume12 Open Interest1070.00Strike Price0.00Turnover84.53%IV2.27%PremiumAug 2, 2024Expiry Date9.19Intrinsic Value100Multiplier1DDays to Expiry24.51Extrinsic Value100Contract SizeAmericanOptions Type0.5694Delta0.0060Gamma34.59Leverage Ratio-8.0864Theta0.0305Rho19.69Eff Leverage0.3065Vega
Regeneron Pharmaceuticals Stock Discussion
Sign in to post a comment
$Regeneron Pharmaceuticals(REGN.US$
🔔 FDA Approves Kevzara® (sarilumab)
» for Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) 🦴
» sBLA approval in patients with pJIA weighing ≥ 63kg
» adds to Kevzara’s position in treating adult chronic inflammatory conditions of moderately to severely active rheumatoid arthritis & polymyalgia rheumatica
🔔 FDA Approves Kevzara® (sarilumab)
» for Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) 🦴
» sBLA approval in patients with pJIA weighing ≥ 63kg
» adds to Kevzara’s position in treating adult chronic inflammatory conditions of moderately to severely active rheumatoid arthritis & polymyalgia rheumatica
3
1
🚨 1 AdCom & 3 PDUFA decisions this week:
$Genfit(GNFT.US$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD(IPSEY.US$ : 🤔
⇨ Elafibranor
‣ Primary biliary cholangitis
‣ PDUFA date: 6/10/24
$Regeneron Pharmaceuticals(REGN.US$ : 🤔
⇨ Kevzara (sarilumab)
‣ Polyarticular juvenile idiopathic arthritis
‣ PDUFA date: 6/10/24
$Bristol-Myers Squibb(BMY.US$ : 🤔
⇨ Augtyro™ (Repotrectinib)
‣ PDUFA date: 6/15/24 (sNDA)
🗓️ Last week’s PDUFAs:
$GlaxoSmithKline(GSK.US$ : Approved 6/7 🎉
⇨ Arexvy
‣ Respiratory s...
$Genfit(GNFT.US$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD(IPSEY.US$ : 🤔
⇨ Elafibranor
‣ Primary biliary cholangitis
‣ PDUFA date: 6/10/24
$Regeneron Pharmaceuticals(REGN.US$ : 🤔
⇨ Kevzara (sarilumab)
‣ Polyarticular juvenile idiopathic arthritis
‣ PDUFA date: 6/10/24
$Bristol-Myers Squibb(BMY.US$ : 🤔
⇨ Augtyro™ (Repotrectinib)
‣ PDUFA date: 6/15/24 (sNDA)
🗓️ Last week’s PDUFAs:
$GlaxoSmithKline(GSK.US$ : Approved 6/7 🎉
⇨ Arexvy
‣ Respiratory s...
9
1
» 15+ upcoming FDA decisions to watch: 👀 👇
$GlaxoSmithKline(GSK.US$ : Arexvy
$Genfit(GNFT.US$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD(IPSEY.US$ : Elafibranor
$Eli Lilly and Co(LLY.US$ : Donanemab - AdCom meeting 🗓️
$Regeneron Pharmaceuticals(REGN.US$ : Kevzara (sarilumab)
$Bristol-Myers Squibb(BMY.US$ : Augtyro™ (Repotrectinib)
$Geron(GERN.US$ : Imetelstat
$Merck & Co(MRK.US$ : V116
$Amgen(AMGN.US$ : BLINCYTO (blinatumomab)
$Sarepta Therapeutics(SRPT.US$ : ELEVIDYS
$Merck & Co(MRK.US$ : KEYTRUDA ...
$GlaxoSmithKline(GSK.US$ : Arexvy
$Genfit(GNFT.US$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD(IPSEY.US$ : Elafibranor
$Eli Lilly and Co(LLY.US$ : Donanemab - AdCom meeting 🗓️
$Regeneron Pharmaceuticals(REGN.US$ : Kevzara (sarilumab)
$Bristol-Myers Squibb(BMY.US$ : Augtyro™ (Repotrectinib)
$Geron(GERN.US$ : Imetelstat
$Merck & Co(MRK.US$ : V116
$Amgen(AMGN.US$ : BLINCYTO (blinatumomab)
$Sarepta Therapeutics(SRPT.US$ : ELEVIDYS
$Merck & Co(MRK.US$ : KEYTRUDA ...
16
Nvidia announced its sixth stock split, with shares set to trade at one-tenth their current price starting June 10, 2024. Before the Q1 2024 earnings call on May 22, when the split was revealed, NVDA closed at $949.50. Since then, the stock has surged past the $1,150 mark, reaching all-time highs. To be eligible for the split shares, investors must own the stock by the market close at 4 pm ET on June 6, 2024. Nvidia's last 4-for-1 split i...
+2
330
76
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Nvidia delighted investors when it announced a 10-for-1 stock split last week. The move may be the start of a trend, as several prominent tech companies trade at prices high enough to tip the scales toward similar splits, according to a note from Bank of America.
The bank highlights 36 S&P 500 companies with stock prices above $500, a level suggesting they may be candidates for splits. $Broadcom(AVGO.US$, $Super Micro Computer(SMCI.US$ , ...
The bank highlights 36 S&P 500 companies with stock prices above $500, a level suggesting they may be candidates for splits. $Broadcom(AVGO.US$, $Super Micro Computer(SMCI.US$ , ...
75
2
See remaining FDA PDUFAs in May 👀👇
$Bristol-Myers Squibb(BMY.US$ : Breyanzi
‣ PDUFA date: 5/31/24 (sBLA)
$Moderna(MRNA.US$ : mRNA-1345
‣ PDUFA date: End of May 2024 (est.) (BLA)
📣 Buckle up & get ready for next month...
June brings 17 PDUFA decisions: 🔥 🔥
$Catalyst Pharmaceuticals(CPRX.US$ : FIRDAPSE® (Amifampridine)
$GlaxoSmithKline(GSK.US$ : Arexvy
$Genfit(GNFT.US$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD(IPSEY.US$ : Elafibranor
$Regeneron Pharmaceuticals(REGN.US$ : Kevzara (sarilumab)
$Bristol-Myers Squibb(BMY.US$ : Augtyro...
$Bristol-Myers Squibb(BMY.US$ : Breyanzi
‣ PDUFA date: 5/31/24 (sBLA)
$Moderna(MRNA.US$ : mRNA-1345
‣ PDUFA date: End of May 2024 (est.) (BLA)
📣 Buckle up & get ready for next month...
June brings 17 PDUFA decisions: 🔥 🔥
$Catalyst Pharmaceuticals(CPRX.US$ : FIRDAPSE® (Amifampridine)
$GlaxoSmithKline(GSK.US$ : Arexvy
$Genfit(GNFT.US$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD(IPSEY.US$ : Elafibranor
$Regeneron Pharmaceuticals(REGN.US$ : Kevzara (sarilumab)
$Bristol-Myers Squibb(BMY.US$ : Augtyro...
8
1
Hello Mooers! ![]()
Recently, there have been signs that World War 3![]()
is coming (*1, *2, *3). Given the current status in the Middle East, Eastern Europe, and the Asia-Pacific, investing has become a difficult task. ![]()
In light of this hypothetical situation![]()
, I have chosen to invest from April 2024 to July 2024 using a three-pronged strategy. ![]()
![]()
![]()
Approach One: Buy the winners
Who are the winners?![]()
During wars, companies that are in the defense, oil, ...
Recently, there have been signs that World War 3
In light of this hypothetical situation
Who are the winners?
30
37
$Novavax(NVAX.US$ $Moderna(MRNA.US$
April 18, 2024
For Global Investor Audience Only
Novavax’s Nuvaxovid XBB.1.5 dispersion for injection, COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2601) is now available to pharmacies across the United Kingdom (U.K.) for private healthcare providers to offer an updated protein-based non-mRNA option as part of the 2024 vaccination season.
To...
April 18, 2024
For Global Investor Audience Only
Novavax’s Nuvaxovid XBB.1.5 dispersion for injection, COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2601) is now available to pharmacies across the United Kingdom (U.K.) for private healthcare providers to offer an updated protein-based non-mRNA option as part of the 2024 vaccination season.
To...
1
$Esperion Therapeutics(ESPR.US$ Esperion (ESPR) stock price has dropped from a recent high of $3.40 a share to $2.31 on FALSE claims of dilution. The price drop offers an amazing buying opportunity.
Huge News On Mar 25.2024 U.S. FDA Approved Broad Labels for NEXLIZET and NEXLETOL, now regular doctors can prescribe and Insurance will...
Huge News On Mar 25.2024 U.S. FDA Approved Broad Labels for NEXLIZET and NEXLETOL, now regular doctors can prescribe and Insurance will...
3
Morning Movers
Gapping up
$Nike(NKE.US$ stock increased by 1.4% after the sportswear company revealed its Olympic kits, aiming to leverage the appeal of top athletes to attract more consumers.
$Alpine Immune(ALPN.US$ stock surged over 36% after Vertex Pharmaceuticals announced its plan to acquire the biotech company for about $4.9 billion in cash, which would give Vertex access to a treatment for an autoimmune kidney disease.
$Rent the Runway(RENT.US$ stock ju...
Gapping up
$Nike(NKE.US$ stock increased by 1.4% after the sportswear company revealed its Olympic kits, aiming to leverage the appeal of top athletes to attract more consumers.
$Alpine Immune(ALPN.US$ stock surged over 36% after Vertex Pharmaceuticals announced its plan to acquire the biotech company for about $4.9 billion in cash, which would give Vertex access to a treatment for an autoimmune kidney disease.
$Rent the Runway(RENT.US$ stock ju...
29
No comment yet
RDK79 : I recognized one word in that lead sentence:)))
But it sounds like good news!!!